drugset / Trial / NCT07232654
Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is a clinical study to evaluate the safety and efficacy of Iparomlimab/Tuvonralimab Injection (QL1706, a Bifunctional Mabpair Product of Anti-PD-1 and Anti-CTLA-4 Antibodies) in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer.
Timeline
- Start
- 2025-11-11
- Primary completion
- 2027-11-30
- Completion
- 2028-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iparomlimab/Tuvonralimab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Background | Cisplatin | Other / unclassified | — | Intravenous |